SPS
PTCT icon

Susquehanna Portfolio Strategies’s PTC Therapeutics PTCT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$921K Hold
13,525
– – 0.01% 649
2025
Q4 		$1.03M Hold
13,525
– – 0.02% 637
2025
Q3 		$830K Buy
13,525
+5,185
+62% +$270K 0.01% 720
2025
Q2 		$407K Buy
+8,340
New +$396K 0.01% 700
2024
Q4 		– Sell
-25,875
Closed -$960K – 252
2024
Q3 		$960K Hold
25,875
– – 0.07% 201
2024
Q2 		$791K Sell
25,875
-4,025
-13% -$130K 0.03% 313
2024
Q1 		$870K Sell
29,900
-50,575
-63% -$1.42M 0.02% 482
2023
Q4 		$2.22M Buy
+80,475
New +$1.84M 0.04% 412

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Susquehanna Portfolio Strategies's PTCT Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 13,525 shares worth $921K. The position accounts for 0.01% of the portfolio, ranked #649.

Susquehanna Portfolio Strategies first reported a position in PTCT in Q4 2023 and has held it in 8 quarters since. The position peaked at $2.22M in Q4 2023. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Susquehanna Portfolio Strategies held 13,525 shares of PTC Therapeutics worth $921K as of Q1 2026.
  • Susquehanna Portfolio Strategies left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #649 holding.
  • Susquehanna Portfolio Strategies first reported a position in PTC Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Susquehanna Portfolio Strategies's PTC Therapeutics position peaked at $2.22M in Q4 2023.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.